EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization

Journal of Hepatology

Volumn 55, Issue 6, 2011, Pages 1309-1316

  Gillmore, Roopinder ^a   Stuart, Sam ^a   Kirkwood, Amy ^b   Hameeduddin, Ayshea ^a   Woodward, Nick ^a   Burroughs, Andrew K ^a   Meyer, Tim ^a,c  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

EASL; Hepatocellular cancer; mRECIST; RECIST; Response rate; Transarterial (chemo) embolisation

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT TOOL; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RECIST CRITERIA; RISK REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME;

EID: 81355147487     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.03.007     Document Type: Article

References (16)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
3. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
4. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2003 429 442
5. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
6. L. Marelli, R. Stigliano, C. Triantos, M. Senzolo, E. Cholongitas, and N. Davies Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies Cardiovasc Intervent Radiol 30 2007 6 25
7. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
8. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
9. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
10. J. Bruix, M. Sherman, J.M. Llovet, M. Beaugrand, R. Lencioni, and A.K. Burroughs Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
11. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
12. J.M. Llovet, A.M. Di Bisceglie, J. Bruix, B.S. Kramer, R. Lencioni, and A.X. Zhu Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
13. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
14. A. Forner, C. Ayuso, M. Varela, J. Rimola, A.J. Hessheimer, and C.R. de Lope Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
15. A.L. Keppke, R. Salem, D. Reddy, J. Huang, J. Jin, and A.C. Larson Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres AJR Am J Roentgenol 188 2007 768 775
16. A. Riaz, F.H. Miller, L.M. Kulik, P. Nikolaidis, V. Yaghmai, and R.J. Lewandowski Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069